At the clinical translation level, biomarker stratification (e.g., the FTO-OTUB1 axis in NPC prognosis) and adaptive clinical trial designs (e.g., basket trials for OTUD3-high DLBCL) may improve precision. This evidence concerns the gene OTUD3 and diffuse large B-cell lymphoma.